Hospira

Global Pharmaceutical Contract Manufacturing Industry

Retrieved on: 
Monday, June 25, 2018
Hospira, Chart, Graph

Table 1: Top 25 Countries Worldwide in Terms of Population: 2015 & 2016 (includes corresponding Graph/Chart)

Key Points: 
  • Table 1: Top 25 Countries Worldwide in Terms of Population: 2015 & 2016 (includes corresponding Graph/Chart)
    Table 3: Comparison of Aging Population by Country (1980, 2015 & 2050): Percentage Share of Population Aged Above-65 Years of the Overall Population for Select Countries (includes corresponding Graph/Chart)
    Table 4: Life Expectancy for Select Countries in Number of Years: 2015E (includes corresponding Graph/Chart)
    Table 7: Worldwide Annual Spending on Drugs by Category (2011 & 2015): Percentage Breakdown of Dollar Sales for Branded Drugs, Generic Drugs, and Others (includes corresponding Graph/Chart)
    Table 8: Leading Players in the Global Finished Dose Pharmaceutical Contract Manufacturing Market (2015): Percentage Breakdown of Revenues for Aenova, Baxter, Catalent, Famar, Fareva, LTS Lohmann, Nipro, Patheon/DPx, Pfizer/Hospira, Vetter and Others (includes corresponding Graph/Chart)
    Table 9: Worldwide Injectables Contract Manufacturing Market by Leading Players (2013): Percentage Breakdown of Value Sales for Baxter, Hospira, Vetter and Others (includes corresponding Graph/Chart)
    Select Key CMO Mergers and Acquisitions: 2014-2016
    Competition Heats Up in Injectables Market, PCMs Expand Capabilities and Service Offerings
    Saneca Sells Registration Dossiers for 20 Products to Xantis, Retains Manufacturing Rights

FDA approves first epoetin alfa biosimilar for the treatment of anemia

Retrieved on: 
Tuesday, May 15, 2018
Medicine, Growth factors, Clinical medicine, Biology, RTT, Erythropoiesis-stimulating agents, Epoetin alfa, Biotechnology, Erythropoietin, Pfizer, Hospira, Zidovudine

SILVER SPRING, Md., May 15, 2018 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection.

Key Points: 
  • SILVER SPRING, Md., May 15, 2018 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection.
  • "Biosimilars can provide greater access to treatment options for patients, increasing competition and potentially lowering costs."
  • Like Epogen/Procrit, Retacrit must be dispensed with a patient Medication Guide that provides information about the drug's uses and risks.
  • The FDA granted approval of Retacrit to Hospira Inc., a Pfizer company.